Company Overview of Solasia Pharma K.K.
Solasia Pharma K.K. engages in developing, marketing, and importing/exporting oncology products. It focuses on developing and commercializing assets in the oncology/hematology fields. The company also provides SP-01 Sancuso, a transdermal system that delivers the anti-emetic and granisetron into the patient’s bloodstream who cannot swallow medicines due to nausea or mucositis; and SP-02 Darinaparsin, a mitochondrial-targeted agent (organic arsenic) for the treatment of various hematologic and solid cancers. It serves customers in Japan, China, Hong Kong, Macau, Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, the Philippines, Thailand, and internationally. Solasia Pharm...
Founded in 2006
Key Executives for Solasia Pharma K.K.
President and Representative Director
Founder and External Director
Head of Product Development Division
Head of Business Development Department
Compensation as of Fiscal Year 2015.
Solasia Pharma K.K. Key Developments
Solasia Pharma Signs Licensing Agreement with Meiji Seika Pharma
Jan 19 15
Meiji Seika Pharma Co. Ltd. and Solasia Pharma, K.K. have entered into a license agreement for the development and commercialization of darinaparsin (intravenous formulation) in Japan. Under the terms of the agreement, Solasia will continue to develop darinaparsin for patients with relapsed and refractory PTCL, conduct Phase II Pan-Asian study and upon completion, seek regulatory approval in Japan. Meiji will then commercialize, distribute and promote darinaparsin for PTCL in Japan. In addition, Meiji also obtained the right to develop and commercialize darinaparsin for indications other than relapsed and refractory PTCL in Japan, the option to manufacture intravenous formulation of darinaparsin and a right of first negotiation relating to the formulations other than the intravenous formulation of darinaparsin. In consideration of the license granted to Meiji, Solasia will receive an initial development payment and, upon successful development, regulatory and sales milestone payments, as well as tiered royalties.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries